BR112013002079A2 - modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer - Google Patents

modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer

Info

Publication number
BR112013002079A2
BR112013002079A2 BR112013002079A BR112013002079A BR112013002079A2 BR 112013002079 A2 BR112013002079 A2 BR 112013002079A2 BR 112013002079 A BR112013002079 A BR 112013002079A BR 112013002079 A BR112013002079 A BR 112013002079A BR 112013002079 A2 BR112013002079 A2 BR 112013002079A2
Authority
BR
Brazil
Prior art keywords
ahr
modifiers
aryl hydrocarbon
hydrocarbon receptor
cancer therapies
Prior art date
Application number
BR112013002079A
Other languages
English (en)
Other versions
BR112013002079B1 (pt
Inventor
David H Sherr
Jennifer Schlezinger
Joshua Robert Giguere
Michael Pollastri
Sarah Haigh Molina
Scott Schaus
Original Assignee
Boston Medical Ct Corp
Univ Northeastern
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Medical Ct Corp, Univ Northeastern, Univ Boston filed Critical Boston Medical Ct Corp
Publication of BR112013002079A2 publication Critical patent/BR112013002079A2/pt
Publication of BR112013002079B1 publication Critical patent/BR112013002079B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer. são fornecidos no presente documento novos agentes que modulam a atividade de ahr para uso em composições terapêuticas e métodos das mesmas para inibição de proliferação de células cancerosas e invasão de células tumorais e metástase. os agentes compreendem inibidore de ahr ou agonistas não constitutivos de ahr de fórmula (i) e (ii) para a inibição do crecimento de células cancerosas e de parãmetros que caracterizam metástases de tumor, tal como a invasidade de células tumorais.
BR112013002079-2A 2010-07-27 2011-07-27 Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer BR112013002079B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36804210P 2010-07-27 2010-07-27
US61/368,042 2010-07-27
PCT/US2011/045526 WO2012015914A2 (en) 2010-07-27 2011-07-27 Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics

Publications (2)

Publication Number Publication Date
BR112013002079A2 true BR112013002079A2 (pt) 2016-11-08
BR112013002079B1 BR112013002079B1 (pt) 2021-09-14

Family

ID=45530686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002079-2A BR112013002079B1 (pt) 2010-07-27 2011-07-27 Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer

Country Status (9)

Country Link
US (2) US10314810B2 (pt)
EP (1) EP2598138B1 (pt)
JP (3) JP6047092B2 (pt)
CN (2) CN107648216B (pt)
AU (1) AU2011282776B2 (pt)
BR (1) BR112013002079B1 (pt)
CA (1) CA2807199C (pt)
EA (1) EA035288B1 (pt)
WO (1) WO2012015914A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107648216B (zh) * 2010-07-27 2021-03-30 波士顿大学管理委员会 作为新型癌症疗法的芳烃受体(AhR)调节剂
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2015130477A1 (en) * 2014-02-14 2015-09-03 The General Hospital Corporation Methods and compositions for the treatment of cancer
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
US10941382B2 (en) 2016-01-29 2021-03-09 Kyoto University Platelet production promoter and method of producing platelets using same
CN106018824B (zh) * 2016-05-18 2017-09-22 上海中医药大学 芳香烃受体在制备药物性心脏病生物标志物中的用途
EP3464248B1 (en) 2016-05-25 2021-09-08 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
CN106075454A (zh) * 2016-07-12 2016-11-09 中国医学科学院基础医学研究所 一种抗肿瘤药物制剂组合
EP3522902A1 (en) 2016-10-04 2019-08-14 Institut National de la Recherche Agronomique Use of ahr agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders
WO2018085775A1 (en) * 2016-11-04 2018-05-11 Ohio State Innovation Foundation Methods and compositions for treating multiple myeloma and increasing antibody dependent cell cytotoxicity by targeting the aryl hydrocarbon receptor
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
CN107312837A (zh) * 2017-06-26 2017-11-03 广州医科大学 一种检测rs2066853位点基因型的引物组及其检测试剂盒和应用
EP3449978A1 (en) 2017-09-01 2019-03-06 Universite Paris Descartes Inhibitors of aryl hydrocarbon receptor for treating soft-tissue sarcoma and preventing neurofibroma growth and/or transformation to malignant peripheral nerve sheath tumors
EP3680325A4 (en) 2017-09-19 2021-06-16 Megakaryon Corporation PLATELET PRODUCTION PROCESS, PLATELET PREPARATION PRODUCTION PROCESS AND BLOOD PREPARATION PRODUCTION PROCESS
EP3713937A2 (en) 2017-11-20 2020-09-30 Ariagen, Inc. Indole compounds as aryl hydrocarbon receptor (ahr) modulators
EP3713926B1 (en) 2017-11-21 2023-06-07 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
US11591311B2 (en) 2017-11-21 2023-02-28 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US11459312B2 (en) 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US11524944B2 (en) 2017-11-21 2022-12-13 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
US11591300B2 (en) 2017-12-21 2023-02-28 The Brigham And Women's Hospital, Inc. Oxazole containing compounds as activators of IDO1 and AhR
WO2020021024A1 (en) 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
US11360080B2 (en) * 2018-08-17 2022-06-14 National Health Research Institutes AhR-ROR-γt complex as a biomarker and therapeutic target for autoimmune disease and IL-17A-associated disease
BR112021003529A2 (pt) 2018-08-24 2021-05-18 Jaguahr Therapeutics Pte Ltd derivados de tetra-hidropiridopirimidina como moduladores de ahr
SG11202101499UA (en) 2018-08-31 2021-03-30 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
JP2022528977A (ja) 2019-04-15 2022-06-16 アリアジェン，インコーポレイテッド キラルインドール化合物およびその使用
KR20220022115A (ko) 2019-04-17 2022-02-24 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및 방법
MX2022001803A (es) 2019-08-12 2022-03-11 Bayer Ag [1,2,4]triazolo[1,5-c]quinazolin-5-aminas.
EP3827824A1 (en) 2019-11-26 2021-06-02 Hercules Pharmaceuticals B.V. Treatment of congenital zika virus syndrome
EP3835432A1 (en) * 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
WO2021148628A1 (en) 2020-01-23 2021-07-29 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体
EP3875098A1 (en) 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
JPWO2021200901A1 (pt) 2020-03-31 2021-10-07
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
CN111777557B (zh) * 2020-07-28 2022-11-22 中国科学院上海有机化学研究所 以芳香联苯烯为骨架的新型抗肿瘤先导化合物及其应用
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN112047880B (zh) * 2020-10-15 2022-11-01 天津科技大学 一类氮杂黄酮衍生物及其作为抗肿瘤药物的应用
CN112807303B (zh) * 2020-12-31 2022-12-30 中国科学院生态环境研究中心 二恶英在抑制细胞迁移中的应用
CN112656789A (zh) * 2020-12-31 2021-04-16 中国科学院生态环境研究中心 Ficz在抑制肿瘤细胞迁移中的应用
CN112807305A (zh) * 2020-12-31 2021-05-18 中国科学院生态环境研究中心 Ch223191在抑制肿瘤细胞迁移中的应用
AU2022292342A1 (en) 2021-06-18 2024-01-18 Megakaryon Corporation Method for producing multinucleated megakaryocyte with enhanced platelet production capability, method for producing platelets, method for producing platelet preparation, and method for producing blood preparation
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling
CN117229284B (zh) * 2023-11-10 2024-02-06 上海泽德曼医药科技有限公司 三环稠杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065574A (en) * 1975-08-29 1977-12-27 The Upjohn Company New method for controlling fungi using 4-chromone, 4-chromanone, 4-chromone oxime and 4-chromanone oxime compounds
US4177276A (en) * 1976-06-16 1979-12-04 Farmitalia Carlo Erba, S.P.A. Substituted 2-vinyl-chromones and process for their preparation
US4177286A (en) * 1976-06-16 1979-12-04 Farmitalia Carlo Erba, S.P.A. Substituted 2-vinyl-chromones and process for their preparation
AU508350B2 (en) * 1976-06-16 1980-03-20 Farmitalia Carlo Erba S.P.A. Substicuted 2-vinyl-chromones
US4183946A (en) * 1976-06-16 1980-01-15 Carlo Erba S.P.A. Substituted 2-vinyl-chromones and process for their preparation
US4183945A (en) * 1976-06-16 1980-01-15 Carlo Erba S.P.A. Substituted 2-vinyl-chromones and process for their preparation
US4143145A (en) * 1977-01-12 1979-03-06 Carlo Erba S. P. A. Substituted 2-vinyl-chromones and process for their preparation
US4127669A (en) * 1977-10-13 1978-11-28 Warner-Lambert Company [(4-Oxo-4H-1-benzopyran-3-yl)oxy] acetic acids and derivatives
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
GB2312621B (en) * 1996-05-02 1998-03-11 Pharma Nord Uk Limited Anti-oxidant medicament
EP0862427A1 (de) * 1996-09-18 1998-09-09 Marigen S.A. Ultramikroemulsionen aus spontan dispergierbaren konzentraten mit antitumoral, antiviral, viruzid und antiparasitär wirksamen estern von bioflavonoid-verbindungen
US6468991B1 (en) * 1997-01-16 2002-10-22 Cyclis Pharmaceuticals, Inc. Method of treating rhinoviral infections
US6180661B1 (en) 1997-04-28 2001-01-30 Marigen, S.A. Bioflavonol-glycoside peresters and their incorporation into pharmacologically active concentrates and ultramicroemulsions
GB9807779D0 (en) * 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
WO2001021608A2 (en) * 1999-09-23 2001-03-29 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Novel flavonoids
WO2002034928A1 (en) * 2000-10-26 2002-05-02 Index Pharmaceuticals Ab Non-human transgenic animal expressing ca-ahr
US7419992B2 (en) * 2001-02-14 2008-09-02 Wisconsin Alumni Research Foundation Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders
JP4587652B2 (ja) * 2002-09-09 2010-11-24 株式会社フラバミン 新規フラボノイド化合物及びその利用
AU2003282999A1 (en) * 2002-10-22 2004-05-13 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
EP1625395B1 (en) * 2003-05-14 2009-09-16 InDex Pharmaceuticals AB Method for identifying tff2 regulating agents
CA2601028C (en) * 2005-03-11 2014-05-27 Howard Florey Institute Of Experimental Physiology And Medecine Flavonoid compounds and uses thereof
GB0805312D0 (en) 2008-03-20 2008-04-30 Medical Res Council Modulation of the immune response
JP2011524374A (ja) * 2008-06-16 2011-09-01 ティグリス ファーマスーティカルズ，インク． アミノフラボンに対する感応性を判定する方法
CA2744407A1 (en) * 2008-11-24 2010-05-27 Giovanni Nicolao Berta New formulations with anti-neoplastic activity
CN107648216B (zh) * 2010-07-27 2021-03-30 波士顿大学管理委员会 作为新型癌症疗法的芳烃受体(AhR)调节剂

Also Published As

Publication number Publication date
BR112013002079B1 (pt) 2021-09-14
US10314810B2 (en) 2019-06-11
JP2018131454A (ja) 2018-08-23
JP2017014252A (ja) 2017-01-19
CN103179968A (zh) 2013-06-26
EP2598138A2 (en) 2013-06-05
EP2598138A4 (en) 2014-04-23
EA201390031A1 (ru) 2013-05-30
JP6621501B2 (ja) 2019-12-18
CN107648216A (zh) 2018-02-02
US20130281525A1 (en) 2013-10-24
US10258600B2 (en) 2019-04-16
AU2011282776B2 (en) 2014-06-12
CA2807199C (en) 2020-07-07
CA2807199A1 (en) 2012-02-02
WO2012015914A3 (en) 2012-05-31
CN107648216B (zh) 2021-03-30
AU2011282776A1 (en) 2013-02-14
WO2012015914A2 (en) 2012-02-02
US20160175278A1 (en) 2016-06-23
AU2011282776A8 (en) 2013-02-21
JP2013538194A (ja) 2013-10-10
EP2598138B1 (en) 2020-05-06
CN103179968B (zh) 2017-10-03
EA035288B1 (ru) 2020-05-25
JP6047092B2 (ja) 2016-12-21

Similar Documents

Publication Publication Date Title
BR112013002079A2 (pt) modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
MX2013008212A (es) Derivados de 7-azaindol.
BR112013016811A2 (pt) compostos e composições terapêuticas
PH12015500181A1 (en) Atx modulating agents
MX367389B (es) Compuestos y sus metodos de empleo.
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
MX2012009030A (es) Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa.
MX2014001218A (es) Tratamiento de cancer de mama.
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
BR112013014076A2 (pt) métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
BR112015002357A2 (pt) compostos e composições ativadores de enzimas
IN2014MN01945A (pt)
MX354697B (es) Composiciones de gel de brimonidina y métodos de uso.
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
BR112013003579A2 (pt) adenovírus, células, e, métodos para tratar câncer
CL2012002753A1 (es) Uso de compuestos derivados de anilinopirimidina sustituida con sulfoximina, inhibidores de pan-cdk, para tratar tumores tales como carcinomas de mama, pancreas, riñon, melanomas malignos, entre otros.
MX2013001150A (es) Marcadores de peso molecular de acetato glatiramero.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.